PAT 401 Week 6 Alterations in Pulmonary Function: Meds

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/66

encourage image

There's no tags or description

Looks like no tags are added yet.

67 Terms

1
New cards
Tocilizumab — Classification

Monoclonal antibody

2
New cards
Tocilizumab — Indications
Severe or critical COVID-19, used in addition to dexamethasone.
3
New cards
Tocilizumab — Mechanism Of Action
Inhibits interleukin-6 (IL-6), an inflammatory cytokine.
4
New cards
Tocilizumab — Desired Effects
Reduces severe inflammation, improves respiratory function, helps prevent organ damage, and decreases ICU stays and mortality in severe COVID-19.
5
New cards
Tocilizumab — Adverse Effects
Headache, dizziness, hypertension, gastrointestinal perforation, abdominal pain, gastritis, mouth ulcerations, neutropenia, thrombocytopenia, rash, infusion reactions, upper respiratory infections, nasopharyngitis, bronchitis, serious infections, anaphylaxis, anti-drug antibodies, and secondary malignancy.
6
New cards
Tocilizumab — Nursing Implications

Monitor for infusion or allergic reactions, infection, and changes in blood cell counts

7
New cards
Nirmatrelvir/Ritonavir (Paxlovid) — Classification
Combination antiviral medication; nirmatrelvir is a protease inhibitor and ritonavir is a pharmacokinetic enhancer.
8
New cards
Nirmatrelvir/Ritonavir (Paxlovid) — Indications
Mild to moderate COVID-19 in adults with a positive viral test who are at high risk of progression to severe illness, hospitalization, or death; initiate within 5 days of symptom onset according to the slide.
9
New cards
Nirmatrelvir/Ritonavir (Paxlovid) — Mechanism Of Action
Nirmatrelvir blocks the SARS-CoV-2 main protease, preventing processing of viral polyprotein precursors and viral replication. Ritonavir inhibits cytochrome P450 metabolism of nirmatrelvir, increasing its blood concentration.
10
New cards
Nirmatrelvir/Ritonavir (Paxlovid) — Desired Effects
Prevents viral multiplication and reduces severe COVID-19 outcomes.
11
New cards
Nirmatrelvir/Ritonavir (Paxlovid) — Adverse Effects
The slides list hypertension and severe allergic reactions; rare effects include Stevens–Johnson syndrome, toxic epidermal necrolysis, and liver problems.
12
New cards
Nirmatrelvir/Ritonavir (Paxlovid) — Nursing Implications

Check the symptom-onset window and watch for severe allergic or skin reactions and liver problems.

13
New cards
Dexamethasone — Classification
Systemic glucocorticoid (corticosteroid).
14
New cards
Dexamethasone — Indications
Severe acute COVID-19 requiring supplemental oxygen; also used for inflammation, allergies, cerebral edema, septic shock, and viral croup (oral or injected).
15
New cards
Dexamethasone — Mechanism Of Action
Suppresses migration of polymorphonuclear leukocytes and fibroblasts and inhibits normal immune responses; glucocorticoids reduce inflammatory mediator activity.
16
New cards
Dexamethasone — Desired Effects
Decreases inflammation, reverses increased capillary permeability, and stabilizes lysosomes.
17
New cards
Dexamethasone — Adverse Effects
Hypertension, seizures, and hyperglycemia. The systemic-glucocorticoid slide also lists adrenal suppression, peptic ulcers, electrolyte imbalances, and masked infection.
18
New cards
Dexamethasone — Nursing Implications
Monitor blood glucose, blood pressure, and infection indicators. The slides emphasize: do not stop systemic glucocorticoids abruptly.
19
New cards
Heparin — Classification
Anticoagulant.
20
New cards
Heparin — Indications
Prevention-dose anticoagulation for severe acute COVID-19.
21
New cards
Heparin — Mechanism Of Action
Binds antithrombin III, inactivating several clotting factors and inhibiting thrombin activity.
22
New cards
Heparin — Desired Effects
Decreases the chance of developing blood clots.
23
New cards
Heparin — Adverse Effects
Severe bleeding or hemorrhage; heparin-induced thrombocytopenia (HIT), in which antibodies activate platelets, form clots, and lower the platelet count.
24
New cards
Heparin — Nursing Implications
Watch for bleeding and signs of HIT, including a falling platelet count; protamine is the heparin antidote discussed on the following slide.
25
New cards
Protamine — Classification
Heparin-reversal agent (antidote).
26
New cards
Protamine — Indications
Serious hemorrhage during heparin therapy.
27
New cards
Protamine — Mechanism Of Action
Binds heparin to form a stable ion pair without anticoagulant activity.
28
New cards
Protamine — Desired Effects
Neutralizes the anticoagulant activity of heparin, making heparin ineffective.
29
New cards
Protamine — Adverse Effects
Severe respiratory distress, anaphylaxis, and pulmonary edema.
30
New cards
Protamine — Nursing Implications

Monitor for respiratory distress and anaphylaxis; onset of action of approximately 5 minutes.

31
New cards
Budesonide — Classification
Glucocorticoid (corticosteroid).
32
New cards
Budesonide — Indications
Nebulized treatment option for viral croup.
33
New cards
Budesonide — Mechanism Of Action
The slides identify budesonide as a glucocorticoid but do not give a drug-specific mechanism; the glucocorticoid class reduces inflammation.
34
New cards
Budesonide — Desired Effects
Reduces airway inflammation in croup (implied by the treatment role; not separately described).
35
New cards
Epinephrine (nebulized) — Classification
The slides do not specify a drug classification for nebulized epinephrine.
36
New cards
Epinephrine (nebulized) — Indications
Severe viral croup.
37
New cards
Epinephrine (nebulized) — Mechanism Of Action
Not specified in the Week 6 slides.
38
New cards
Epinephrine (nebulized) — Desired Effects
Used for severe croup management; the slides do not separately describe its desired effect.
39
New cards
Epinephrine (nebulized) — Nursing Implications
The slides identify nebulized epinephrine alongside oxygen for severe croup but give no drug-specific monitoring instructions.
40
New cards
Palivizumab — Classification
RSV-specific monoclonal antibody.
41
New cards
Palivizumab — Indications
Preventive treatment against RSV-associated bronchiolitis in infants.
42
New cards
Palivizumab — Mechanism Of Action
The slides identify it as an RSV-specific monoclonal antibody but do not detail a mechanism.
43
New cards
Palivizumab — Desired Effects
Can reduce morbidity from RSV bronchiolitis in infants.
44
New cards
Azithromycin — Classification
Macrolide antibiotic.
45
New cards
Azithromycin — Indications
Respiratory tract infections, including pneumonia.
46
New cards
Azithromycin — Mechanism Of Action
Binds bacterial ribosomal subunits to suppress protein synthesis, preventing production of proteins required for growth.
47
New cards
Azithromycin — Desired Effects
Bacteriostatic effect: stops bacterial growth.
48
New cards
Azithromycin — Adverse Effects
Skin reactions and hepatotoxicity.
49
New cards
Azithromycin — Nursing Implications
Check liver enzymes, as emphasized on slide 66.
50
New cards
Amoxicillin — Classification
Penicillin antibiotic.
51
New cards
Amoxicillin — Indications
Respiratory tract infections, including pneumonia.
52
New cards
Amoxicillin — Mechanism Of Action
Binds to bacterial cell-wall targets, interferes with cell-wall replication, and causes bacterial cell-wall autolysis.
53
New cards
Amoxicillin — Desired Effects
Bactericidal action: kills susceptible bacteria.
54
New cards
Amoxicillin — Adverse Effects
Allergic reactions, including anaphylaxis.
55
New cards
Amoxicillin — Nursing Implications

Assess for and monitor allergic reactions or anaphylaxis

56
New cards
Ciprofloxacin — Classification
Fluoroquinolone antibiotic.
57
New cards
Ciprofloxacin — Indications
Respiratory infections (including pneumonia), bone/joint, gastrointestinal and ophthalmic infections, sinusitis, prostatitis, and post-exposure prophylaxis for anthrax, plague, or tularemia.
58
New cards
Ciprofloxacin — Mechanism Of Action
Inhibits bacterial DNA gyrase and topoisomerase IV, enzymes needed for bacterial DNA synthesis and replication.
59
New cards
Ciprofloxacin — Desired Effects
Bactericidal activity against gram-negative bacteria.
60
New cards
Ciprofloxacin — Adverse Effects
Common: nausea, vomiting, diarrhea. Serious: dysrhythmias and liver failure. CNS: dizziness, headache, sleep disturbances.
61
New cards
Ciprofloxacin — Nursing Implications
Antacids, ferrous sulfate, and sucralfate decrease ciprofloxacin absorption; avoid taking them together and follow spacing instructions. Monitor for adverse GI, CNS, cardiac, and liver effects.
62
New cards
Cefotaxime — Classification
Cephalosporin antibiotic.
63
New cards
Cefotaxime — Indications
Gram-negative and penicillin-resistant infections, and infections in some patients with penicillin allergy, including serious lower respiratory, central nervous system, genitourinary, bone/joint, bloodstream infections, and septicemia.
64
New cards
Cefotaxime — Mechanism Of Action
Binds penicillin-binding proteins to inhibit bacterial cell-wall synthesis, leading to cell lysis.
65
New cards
Cefotaxime — Desired Effects
Bactericidal action against gram-negative pathogens.
66
New cards
Cefotaxime — Adverse Effects
Possible cross-sensitivity with penicillin, gastrointestinal upset, and reduced prothrombin levels.
67
New cards
Cefotaxime — Nursing Implications
Check for penicillin-related cross-sensitivity and monitor for GI effects and bleeding concerns. The slides specify IM or IV administration because cefotaxime is not absorbed from the GI tract.